The Lancet Haematology

1. Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis

   Publication date: July 2022

   Source: The Lancet Haematology, Volume 9, Issue 7

   Author(s): Christine M Campbell, Daniel R Owen, Amanallah Montazeripouragha, Iain McCormick, David C Fajgenbaum, Luke Y C Chen

2. Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemia

   Publication date: July 2022

   Source: The Lancet Haematology, Volume 9, Issue 7

   Author(s): Nicholas J Short, Hagop Kantarjian

3. Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?

   Publication date: July 2022

   Source: The Lancet Haematology, Volume 9, Issue 7

   Author(s): Michael J Hochman, Amy E DeZern

4. Associations between non-anaemic iron deficiency and outcomes following elective cardiac surgery (IDOCS): a prospective cohort study

   Publication date: July 2022

   Source: The Lancet Haematology, Volume 9, Issue 7

   Author(s): Lachlan F Miles, Vanessa Pac Soo, Sabine Braat, Jordan Bade-Boon, Stephane Heritier, Andrew A Klein, Paul S Myles, Toby Richards, Joel Symons, Kate L Burbury, David A Story

5. Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial

   Publication date: July 2022

   Source: The Lancet Haematology, Volume 9, Issue 7

   Author(s): Feng Xue, Huiyuan Li, Xia Wu, Wei Liu, Feixu Zhang, Dingyue Tang, Yunfei Chen, Wentian Wang, Ying Chi, Jing Zheng, Zengmin Du, Wei Jiang, Chen Zhong, Jun Wei, Ping Zhu, Rongfeng Fu, Xiaofan Liu, Lingling Chen, Xiaolei Pei, Junjiang Sun

6. SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial

   Publication date: July 2022

   Source: The Lancet Haematology, Volume 9, Issue 7

   Author(s): Yuqin Song, Yanyan Liu, Zhi-Ming Li, Lanfang Li, Hang Su, Zhengming Jin, Xuelan Zuo, Jianyuan Wu, Hui Zhou, Kunyan Li, Chuan He, Jianfeng Zhou, Junyuan Qi, Siguo Hao, Zhen Cai, Yijing Li, Weiwei Wang, Xiaojing Zhang, Jianjun Zou, Jun Zhu

7. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study

   Publication date: July 2022

   Source: The Lancet Haematology, Volume 9, Issue 7

   Author(s): Francesco Passamonti, Francesca Palandri, Guray Saydam, Jeannie Callum, Timothy Devos, Paola Guglielmelli, Alessandro M Vannucchi, Evren Zor, Mike Zuurman, Geralyn Gilotti, Yifan Zhang, Martin Griesshammer

8. The HemeOncBuddy app—a new tool to keep up with the clinical trial storm

   Publication date: July 2022

   Source: The Lancet Haematology, Volume 9, Issue 7

   Author(s): Veli Bakalov

9. Correction to Lancet Haematol 2022; 9: e200–07

   Publication date: July 2022

   Source: The Lancet Haematology, Volume 9, Issue 7

   Author(s):

10. Addressing inequity in access to palliative care for patients with non-malignant or benign haematological diseases

    Publication date: July 2022

    Source: The Lancet Haematology, Volume 9, Issue 7

    Author(s): Kwok Ying Chan, Harinder Singh Harry Gill, Desmond Y H Yap

11. Transparently report on the process of moving from evidence to recommendation – Authors' reply

    Publication date: July 2022

    Source: The Lancet Haematology, Volume 9, Issue 7

    Author(s): Jannik Stemler, Nicole Skoetz, Oliver A Cornely

12. Transparently report on the process of moving from evidence to recommendation

    Publication date: July 2022

    Source: The Lancet Haematology, Volume 9, Issue 7

    Author(s): Meng Lv, Xufei Luo, Tong Chen, Yaolong Chen

13. Counting the carbon cost of heparin: an evolving tragedy of the commons?

    Publication date: July 2022

    Source: The Lancet Haematology, Volume 9, Issue 7

    Author(s): Bingwen Eugene Fan, Emmanuel J Favaloro

14. Climate change and haematology: perspectives from the Philippines

    Publication date: July 2022

    Source: The Lancet Haematology, Volume 9, Issue 7

    Author(s): Bradley Ashley G Ong, Aubrey Melody R Rocimo, Josephine Anne C Lucero

15. Iron deficiency: effects beyond anaemia?

    Publication date: July 2022

    Source: The Lancet Haematology, Volume 9, Issue 7

    Author(s): Suma Choorapoikayil, Patrick Meybohm

16. Factor IX Padua for haemophilia B gene addition: universal adaptation and repeated success

    Publication date: July 2022

    Source: The Lancet Haematology, Volume 9, Issue 7

    Author(s): Lindsey A George

17. Easy does it! New EZH2 inhibitor SHR2554 is safe and active in relapsed or refractory lymphoma

    Publication date: July 2022

    Source: The Lancet Haematology, Volume 9, Issue 7

    Author(s): Yun Kyoung Ryu, Jennifer E Amengual

18. Ruxolitinib in patients with polycythemia vera with hydroxyurea resistance or intolerance

    Publication date: July 2022

    Source: The Lancet Haematology, Volume 9, Issue 7

    Author(s): Sangeetha Venugopal, John Mascarenhas

19. The dystopia of enforced childbirth

    Publication date: July 2022

    Source: The Lancet Haematology, Volume 9, Issue 7

    Author(s): The Lancet Haematology

20. [¹⁸F]FDG-PET-CT in neutropenic fever: a picture searching for a frame(work)

    Publication date: Available online 28 June 2022

    Source: The Lancet Haematology

    Author(s): R Scott Stephens

21. [¹⁸F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial

    Publication date: Available online 28 June 2022

    Source: The Lancet Haematology

    Author(s): Abby Douglas, Karin Thursky, Timothy Spelman, Jeff Szer, Ashish Bajel, Simon Harrison, Shio Yen Tio, Olivia Bupha-Intr, Michelle Tew, Leon Worth, Benjamin Teh, Lynette Chee, Ashley Ng, Dennis Carney, Amit Khot, Gabrielle Haeusler, Michelle Yong, Jason Trubiano, Sharon Chen, Rodney Hicks

22. European Hematology Association Hybrid Congress 2022

    Publication date: Available online 20 June 2022

    Source: The Lancet Haematology

    Author(s): Owen Stretton

23. The long and short of antibiotic management for neutropenic fever in patients with haematological malignancy

    Publication date: Available online 9 June 2022

    Source: The Lancet Haematology

    Author(s): Benjamin W Teh

24. Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial

    Publication date: Available online 9 June 2022

    Source: The Lancet Haematology

    Author(s): Nick A de Jonge, Jonne J Sikkens, Sonja Zweegman, Aart Beeker, Paula Ypma, Alexandra H Herbers, Wies Vasmel, Arne de Kreuk, Juleon L L M Coenen, Birgit Lissenberg-Witte, Mark H H Kramer, Michiel A van Agtmael, Jeroen J W M Janssen

25. A curious case of a neutrophilic horn

    Publication date: June 2022

    Source: The Lancet Haematology, Volume 9, Issue 6

    Author(s): Tobias M Benoit, Max J Rieger, Sebastian M Stolz

26. The case for classical haematology: the impact of a name and the future of a field

    Publication date: June 2022

    Source: The Lancet Haematology, Volume 9, Issue 6

    Author(s): Hanny Al-Samkari, Alison W Loren, Alfred I Lee

27. An integrated approach to cardioprotection in lymphomas

    Publication date: June 2022

    Source: The Lancet Haematology, Volume 9, Issue 6

    Author(s): Maja V Maraldo, Mario Levis, Alessandro Andreis, Saro Armenian, James Bates, Jessica Brady, Alessandra Ghigo, Alexander R Lyon, Charlotte Manisty, Umberto Ricardi, Marianne C Aznar, Andrea Riccardo Filippi

28. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study

    Publication date: June 2022

    Source: The Lancet Haematology, Volume 9, Issue 6

    Author(s): Naveen Pemmaraju, Jacqueline S Garcia, Jalaja Potluri, Jason G Harb, Yan Sun, Paul Jung, Qin Q Qin, Srinivas K Tantravahi, Srdan Verstovsek, Claire Harrison

29. Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial

    Publication date: June 2022

    Source: The Lancet Haematology, Volume 9, Issue 6

    Author(s): Pablo L Ortiz-Romero, Lidia Maroñas Jiménez, Cristina Muniesa, Teresa Estrach, Octavio Servitje, Ricardo Fernández-de-Misa, Fernando Gallardo, Onofre Sanmartín, Erica Riveiro-Falkenbach, Nuria García-Díaz, Rosa Vega, David Lora, Concepción Postigo, Blanca Jiménez, Margarita Sánchez-Beato, José Pedro Vaqué, José Luis Rodríguez Peralto, Agustín Gómez de la Cámara, Javier de la Cruz, Miguel Ángel Piris Pinilla

30. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial

    Publication date: June 2022

    Source: The Lancet Haematology, Volume 9, Issue 6

    Author(s): Huafeng Wang, Liping Mao, Min Yang, Pengxu Qian, Huan Lu, Hongyan Tong, Wanzhuo Xie, De Zhou, Xin Huang, Yungui Wang, Gaixiang Xu, Ying Lu, Juying Wei, Wenyuan Mai, Xiujin Ye, Haitao Meng, Yaojia Shen, Jian Huang, Wenjuan Yu, Jie Sun